SecBot SecBot
SECBOTREPLAY Home › Report › CYTK

CYTK · Cytokinetics reported its transition to a commercial-stage company…

CYTOKINETICS INC · 8-K filed Feb 24, 2026 at 16:13 ET

At the news

MIXEDIMPACT 7/10

8-K filed Feb 24, 2026 at 16:13 ET

Cytokinetics reported its transition to a commercial-stage company following FDA, China, and EU approvals of MYQORZO for obstructive HCM, with the U.S. launch underway. The company posted a wider net loss of $785M in 2025 due to increased R&D and commercial readiness spending, while maintaining ~$1.22B in cash. It provided 2026 guidance with $830M–$870M in combined R&D and SG&A expenses.

  • MYQORZO approved in U.S., China, and EU for symptomatic obstructive HCM; U.S. launch began in January 2026 with first prescriptions dispensed.
  • Total 2025 revenue was $88.0M (up from $18.5M in 2024), driven by a $52.4M technology transfer payment to Bayer and $15.0M in milestone revenue from MYQORZO approvals.
  • 2025 net loss was $785.0M (vs. $589.5M in 2024); Q4 2025 net loss was $183.0M (vs. $150.0M in Q4 2024), reflecting higher R&D and G&A expenses for commercialization.
  • Cash, cash equivalents, and investments were $1.22B as of December 31, 2025, down from $1.25B in Q3; excluding a $100M loan draw, cash declined by $134M in Q4.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access